A bioequivalence study comparing two formulations of lopinavir/ritonavir capsules

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 4, 2008, Pages 204-210

  Tippabhotla, S K ^a   Thudi, N R ^c   Raghuvanshi, R ^a   Khuroo, A H ^a   Gurule, S ^a   Mishra, S ^a   Monif, T ^a   Lao, V K C ^b  

^a RANBAXY LABORATORIES LTD   (India)

^b Biovail Contract Research   (Canada)

^c Ranbaxy Pharmaceuticals Canada Inc   (Canada)

Author keywords

Fixed dose combination; Lopinavir and ritonavir; Males and females; Nonfasting; Pharmacokinetics

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CAUCASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NEGRO; NORMAL HUMAN; PALLOR; PRACTICE GUIDELINE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STOMACH DISCOMFORT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; VOMITING;

EID: 41849132154     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46204     Document Type: Article

References (13)

1. Canta F, Marrone R, Bonora S, D 'Avolio A, Sciandra M, Sinicco A, De Rosa FG, Perri GD. Pharmacokinetics and hepatotoxicity of lopinavir/ ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother. 2005; 55: 280-281.
2. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003; 63: 769-802.
3. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Panel on clinical practices for treatment of HIV. Guidelines for using anti-retroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002; 137: 381-433.
4. Food and Drug Administration. Guidance for Industry: Bioavailability and bioequivalence studies for orally adnñnistered drug products - general considerations. Available at http://www.fda.gov/ cder/guidance/5356-fnl.pdf. 2003.
5. Food and Drug Administration. Guidance for Industry: fixed dose combinations - co-packaged drug products and single-entity versions of previously approved antiretroviral for the treatment of HIV. Department of Health and Human Service: Centre for Drug Evaluation and Research: 2006; (CDER).
6. Hoffmann C, Rockstroh JK, Kamps BS. HIV. Medicine. 2006; 14: 852. www.HIVMedicine.com.
7. Huisman MT, Smith JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of protease inhibitors. AIDS. 2000; 14: 237-242.
8. Joanna ZP, Federico P, Sonja JKC, Jianling L, Alicia L, Concepción C, Juan AGC, Barbara DS, Scott CB, José A. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol. 2006; 46: 265.
9. Moltó J, Valle M, Blanco A, Negredo E, DelaVarga M, Miranda C, Miranda J,Domingo P, Vilaró J, Tural C, Costa J, Barbano MY, Bonaventura C. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus-coinfected patients without liver function impairment: influence of liver fibrosis. Clin Pharmacokinet. 2007; 46: 85-92.
10. Oki T, Usami Y Nakai M, Sagisaka M, Ito H, Nagaoka K, Mamiya N, Yamanaka K, Utsumi M, Kaneda T. Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers. Biol Pharm Bull. 2004; 27: 261-265.
11. Porte CJL, Clobbers EPH, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004; 48: 1553-1560.
12. Rolf PG, Van H, Marc B, Pearl C, Isabelle S, Bobby MC, Brian CF, William DC. Time-dependent interaction between Lopinavir, Ritonavir and Fexofenadine. J Clin Pharmacol. 2006; 46: 758.
13. Rowland M, Tozer TN. Concepts and application. Lippincott, Williams and Wilkins, Baltimore, MD, USA; 1995. p. 367-393.